(Q45754894)

English

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

scientific article published on 15 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (English)

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Kathleen I. Pritchard

14

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

7

object named as

Jose Baselga

1 reference

Europe PubMed Central

15 December 2017

6

object named as

Patrick Neven

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Gabriel N Hortobagyi

9

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

3

object named as

Hope S Rugo

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

19

object named as

Tarek Sahmoud

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

author name string

Howard A Burris

1

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Fabienne Lebrun

2

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

J Thaddeus Beck

4

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Martine Piccart

5

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Katarina Petrakova

8

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Anna Komorowski

10

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Edmond Chouinard

11

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Robyn Young

12

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Lee Bennett

15

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Jean-Francois Ricci

16

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Hounayda Bauly

17

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Tetiana Taran

18

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Shinzaburo Noguchi

20

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

language of work or name

0 references

publication date

15 March 2013

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

119

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

10

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

1908-1915

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

CNS metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Brain metastases: the HER2 paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Quality of life in patients undergoing systemic therapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Methods to explain the clinical significance of health status measures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Quality of life measurement: bibliographic study of patient assessed health outcome measures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Surviving cancer: a comparison of 5-year disease-free breast cancer survivors with healthy women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Interpreting clinically significant changes in patient-reported outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

21 January 2018

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28010

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28010

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

1 reference

Europe PubMed Central

15 December 2017

http://europepmc.org/abstract/MED/23504821

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45754894&oldid=2160362227"